There is an increasing trend towards long-term frozen storage of haematopoietic stem cells. For such stem cells, harvested from peripheral blood (PB) or BM, it is not known if stem cell viability decreases with time. In this study, 31 separate bags of stem cell product (SCP) stored for 11-19 years (median 15 years) were assessed for total nucleated cell (TNC) count, colony forming unitgranulocyte/macrophage (CFU-GM), CD34
INTRODUCTION
Haematopoietic stem cells can be obtained from BM, 1 cord blood 2 or mobilised peripheral blood (PB) 3 and can be stored frozen. 4 The majority of these stem cell products (SCPs) are thawed and used within months of harvesting but, increasingly, long-term storage of stem cells may also be performed as a precautionary procedure. Few data are available on the status of BM and PBSCs stored for over a decade. Studies performed on cord blood stem cells have reported that storage for up to 15 years does not significantly decrease recovery. [5] [6] [7] [8] However, studies on PB-or BM-derived stem cells have been limited and predominantly analysed the effects of relatively short (median p2 years) storage. [9] [10] [11] [12] A single study has suggested that SCPs stored for longer periods (median 9 years) may be inadequate for transplant 13 but did not compare pre-and post-storage results for individual samples.
The study presented here investigated stem cells stored for 11-19 years and the effect that cryopreservation had on parameters measured both pre-and post storage.
MATERIALS AND METHODS Samples
SCPs that had been stored in a single transplant centre for 11-19 years were identified. All the SCPs had undergone controlled rate freezing at À 1 1C per minute for 80 min down to À 80 1C before being placed and stored in the vapour phase of liquid nitrogen at À 180 1C. The freezing mixture of 20% DMSO and 80% plasma had been added in equal volume to that of the buffy coat cells, giving a final concentration of DMSO in the stored product of 10%. This procedure had not changed over the 20 years. Upon thawing, the SCPs were tested for white cell count (WCC), total nucleated cell (TNC) count, colony forming unit-granulocyte/macrophage (CFU-GM), CD34 þ cell number and viability. The results were compared with the original SCP data obtained at the time of stem cell harvest.
WCC and TNC
The 'current WCC' ( Â 10 9 /L) was obtained using a Sysmex XE 2100 (Sysmex New Zealand Ltd, Auckland, New Zealand). To allow comparison with the original data, the current WCC was multiplied by the original volume of SCP obtained pre-freeze but post addition of DMSO. The result was the 'current TNC' ( Â 10 9 /L). The 'original WCC' was measured on a Coulter STKS (Beckman Coulter New Zealand Ltd, North Shore, New Zealand) and was multiplied by the original volume of SCP pre-freeze and post DMSO to give the 'original TNC'. By dividing the current TNC by the original TNC and multiplying by 100, the 'percentage recovery of TNC' was obtained.
Viability
The 'current viability' of the SCP was determined immediately upon thawing using a standard trypan blue dye exclusion method.
14 In short, 50 mL 0.4% trypan blue was added to 50 ml of sample in a Neubauer counting chamber. The stained and unstained cells were counted and then a standard viability calculation was performed. A single operator analysed all the samples, thereby decreasing inter-assay variability. The 'original viability' was obtained from the records and had also been determined using the trypan blue exclusion method using the post-DMSO and post-freeze/thaw test sample. By dividing the current viability by the original viability and multiplying by 100, the 'percentage recovery of viability' was obtained.
CFU-GM
The current CFU-GM assay was performed using Methocult GF H4534 (StemCell Technologies, Vancouver, British Columbia, Canada). Known concentrations of viable cells from the SCP were plated in duplicate at two different concentrations. Following incubation, resulting colonies on each plate were counted using inverted phase microscopy and an average colony count calculated from the quadruplicate plates. The average colony count (per Â 10 4 cells) was multiplied by the 'current TNC' and then by the percentage viable cells measured using trypan blue. This allowed direct comparison with the original CFU-GM result. The original CFU-GM utilised an agar method, which used total cells for plating rather than viable cells. In-house comparison (data not shown) showed that the agar and methocult methods correlated well (Pearson's r ¼ 0.94; P ¼ 0.0006), with the methocult method always yielding higher results by an average factor of 1.7. As was the standard practice at the time, the original CFU-GM assay noted for this study was performed on a portion of the original SCP after the addition of DMSO and after controlled rate freezing and re-thaw. Finally, by dividing the current CFU-GM by the original CFU-GM and multiplying by 100, the 'percentage recovery of CFU-GM' was obtained.
CD34
þ number
The current absolute CD34 þ cell count (cells per mL) was obtained using a single platform method on a Beckman-Coulter Cytomics FC 500 and using Beckman-Coulter Stem Kit IM3630 reagents (Immunotech SAS, Marseille, France). To allow direct comparison with original data, this result was multiplied by the original product volume, post DMSO but pre-freeze, to give the 'current CD34 þ cell count'. The 'original CD34 þ cell count' had been performed using a dual platform method, the flow cytometer giving a percentage CD34 þ cells and this result being multiplied by the 'original TNC'. By dividing the current CD34 þ cell count by the original CD34 þ cell count and multiplying by 100, the 'percentage recovery of CD34 þ cell count' was obtained. The 'CD-Chex CD34' (Streck, Omaha, NE, USA) quality control system gave a CV (coefficient of variation) for the CD34 þ assay at the time of the study of 11.3%.
Statistics
Prism 5 for Windows version 5.01 (GraphPad software Inc., La Jolla, CA, USA) was used for statistical analysis. The paired t-test was first used to compare 'original' with 'current' results. Bland Altman plots were then generated to assess whether the 'difference' or the 'ratio' of 'original' vs 'current' results were the most appropriate to use to compare change over time. The 'ratio' method was most appropriate and for each variable, the ratio of current/original ( Â 100) (named 'percent recovery') was plotted against time. Linear regression analysis was then used to determine any association of the characteristic with time.
RESULTS
A total of 31 separate bags of SCP from 25 patients stored for 11-19 years (median 15 years) were tested. In all, 18 were BM and 13 were PB. Six patients had two separate bags from the same harvest tested. The two sets of results for each of the six patients were used to confirm reproducibility of the CD34 testing when performed on thawed, long-term frozen stem cells. Basic data are shown in Table 1. WCC and TNC Both the original and current TNC counts were available for 30 bags of stem cells. The median recovery of TNC was 88% and linear regression analysis demonstrated a significant decrease (P ¼ 0.003) in TNC recovery with longer time stored (Figure 1 ). The linear regression slope decreased at a rate of 0.363 per month, giving an estimated time to 50% TNC recovery of 279 months. Two results appeared to be outliers (samples 26 and 27, the highest points on Figure 1 ). However, the decrease in TNC recovery remained statistically significant (P ¼ 0.01), following exclusion of these two points from the analysis. Based on the available clinical and laboratory data, there was no readily identifiable reason for the two outlying results.
Viability
Both the original and current cell viability scores were available for all the 31 bags of stem cells. The median recovery of viability was 58% and linear regression analysis demonstrated a significant decrease (P ¼ 0.01) in viability recovery with longer storage time of the product (Figure 2 ). The linear regression slope decreased at a rate of 0.282 per month, giving an estimated time to 50% recovery of viability of 195 months. When the 13 samples of PB were analysed alone, the decrease in viability recovery with time remained statistically significant (P ¼ 0.001).
CFU-GM
Both the original and current post-thaw CFU-GM counts were available for 22 of the bags of stem cells. The median current CFU-GM results were lower than the current CFU-GM results (71 vs 43 colonies) but this did not reach statistical significance (P ¼ 0.09). The median CFU-GM recovery was 56.5% and linear regression analysis detected no significant change (P ¼ 0.49) in CFU-GM recovery with longer storage time ( Figure 3 ).
Both the original and current total CD34 þ counts were reliably available for 10 of the bags of stem cells, all of which were PB harvests. The original CD34 þ counts were significantly higher than the current counts (median 47 vs 25 Â 10 6 ; P ¼ 0.0016). The median CD34 þ recovery was 55% and linear regression analysis demonstrates a significant decrease in recovery of CD34 þ cells (P ¼ 0.0007) with increase in time stored (Figure 4) . The linear regression slope decreased at a rate of 2.38 per month, giving an estimated average time to 50% recovery of CD34 þ of 146.1 months.
In six patients, a single SCP had been stored in multiple bags, and two bags from each of these patients were analysed separately. These pairs of SCP thereby act as duplicate samples for estimating the reproducibility of the CD34 þ assay when performed on thawed long-term frozen stem cells. The coefficient of variation for these duplicate samples was 14% (95% CI 3.9-25).
DISCUSSION
There is an increasing trend towards long-term storage of human haematopoietic stem cells. Although some data have been reported on the effects of long-term (up to 15 years) storage of stem cells obtained from cord blood, [5] [6] [7] [8] there are few data to show how stem cells harvested from BM or PB fare with time. A study on BM stored for a median of 2.7 years and a separate study of both BM and PB stored for a median of 2.8 years demonstrated that the thawed products were capable of engraftment but did not examine how the markers of potential engraftment changed with time for each specimen. 15, 16 For each study, it is possible that very high initial stem cell yields, even with significant loss over time, could still give engraftment after a relatively short cryo-storage time of 2.8 years. Spurr et al. 13 examined surrogate markers of potential engraftment such as CD34 þ cells and CFU-GM after a median of 9.5 years and found that deterioration of stem cell quality and viability may occur and that many of the long-term stored SCPs were not adequate for transplantation. They did not directly compare the original and current results for each individual specimen, but the data indicated that the stem cells stored the longest had the lowest CD34 þ cell counts and CFU-GM. Other studies have also shown a decrease in CFU-GM or engraftment with long-term storage but are less applicable because of the use of less extreme freezing temperatures 17 or the use of animal models 18 and studies that report no decrease in SCP markers have been limited by relatively short median storage times. [9] [10] [11] [12] 19 In this study, recovery of SCP, TNC, cell viability and total CD34 þ cell count decreased as storage time, up to 19 years, increased. No previous study has analysed stem cells stored for this long and no previous study, using PB or BM stem cells, has directly compared individual samples results from the time of original harvest with the current time post long-term storage. The estimated half-lives (time to 50% recovery) for TNC, cell viability and CD34 þ cell counts were 410 years and it is unlikely that product deterioration with such long half-lives would have been noted in previous studies with median storage times of 2.7 or 2.8 years. 15, 16 Limitations of the study include the fact that most of the older stored stem cells were from BM and the more recently stored cells were from PB harvests, although it is not known if this would make any difference to the recovery of the measured parameters. In addition, the methodologies used for determining CD34 þ cells, TNC and CFU-GM have changed over the period of sample storage, which provides a potential source of bias in the interpretation of the data. However, all the pre-cryopreservation and post-cryopreservation samples were analysed using the same methodologies, therefore any effects due to methodological changes should be consistent across all the patients and should not bias any observed changes with time. Of note, the 'current viability' was analysed using both trypan blue and the 7-amino actinomycin D methods (data not shown) and, in line with previous reports, 20, 21 the results of these tests correlated well (Pearson's r ¼ 0.71). As the 7-amino actinomycin D results were not available from the original time of storage, and to minimise bias, only the trypan blue results pre-and post storage are presented. The cells analysed in the current study were harvested in a single institution and were frozen and stored the same way at À 180 1C in the vapour phase of liquid nitrogen. Cells that underwent long-term storage had been stored in a separate liquid nitrogen dewar from those in routine use, thus significantly decreasing the number of times the dewar was accessed and the potential effects of transient warming. Storage conditions have significant effects on recoveries, particularly 'transient warming events' associated with the removal and/or placement of stem cell units in the dewars. Although temperature monitoring and maintenance occurred, records were not kept locally that would allow assessment of exposure to transient warming events to be determined. It is possible that the deterioration over time observed in this study may reflect, in part, the cumulative exposure to transient warming events rather than an intrinsic loss in the viability of frozen stem cells over time. Although storage of units in liquid-phase N 2 may reduce transient warming events, this must be balanced against the increased risk of viral infection associated with liquid-phase storage. 22 The use of inventory management systems to monitor exposure to transient warming events may provide a means of evaluating the potential for decline in stored products.
Engraftment of stem cells was not examined in this study. Neither the CD34 þ counts nor the CFU-GMs are perfect surrogate markers for stem cell engraftment, but the CD34 þ count is currently recognised as being the gold standard 23 and therefore provides the easiest means of evaluating the adequacy of stored products.
Although engraftment is the ultimate in-vivo test of the adequacy of stored stem cells, it will not, as a test, quantitate deterioration of SCPs. Engraftment at a time point x will depend largely upon the initial yield of stem cells as well as the rate of deterioration. By using a finite cut off measure such as engraftment, adequacy of SCPs cannot be extrapolated beyond the time point given. The current study addresses this issue by comparing the results obtained from individual SCPs at the time of harvest with results on the same specimen 11-19 years later. By showing that recovery changes with time, it is possible to see that all the PB or BM SCPs may eventually become inadequate, even with very high initial cell yields. Caution should be exercised when considering use of stem cells that have been stored for very long periods of time.
